

# Diazepines II. A New Synthesis of 4*H*-Pyrrolo[1,2-*a*]-[1,4]benzodiazepine (1)

Yasutaka Kayama, Takeshi Hara (2), Kazuhiko Itoh and Tamiko Sunami

Teijin Institute for Biomedical Research, 4-3-2 Asahigaoka, Hino, Tokyo 191, Japan

Received September 10, 1976

A convenient synthesis of a 4*H*-pyrrolo[1,2-*a*][1,4]benzodiazepine is described. 2,5-Dimethoxy-2-methyl-5-phthalimidomethyltetrahydrofuran (**3**) was prepared starting from 2-methyl-5-phthalimidomethylfuran (**1**). The condensation of 2-amino-5-chlorobenzophenone with **3** to give 5-chloro-2-(2-methyl-5-phthalimidomethylpyrrol-1-yl)benzophenone (**4**), the treatment of which with hydrazine hydrate afforded 8-chloro-1-methyl-4*H*-pyrrolo[1,2-*a*][1,4]benzodiazepine (**5**).

*J. Heterocyclic Chem.*, **14**, 171 (1977).

Sir:


Although there is considerable work (3,4) in recent years for the synthesis of tricyclic diazepine compounds having anxiolytic activity, but a single synthesis of the heterocyclic system, 4*H*-pyrrolo[1,2-*a*][1,4]benzodiazepine has thus far been reported (5). We now wish to report the efficient synthesis of 8-chloro-1-methyl-6-phenyl-4*H*-pyrrolo[1,2-*a*][1,4]benzodiazepine.

Treatment of 2-methyl-5-phthalimidomethylfuran (**1**) with bromine in a mixture of methylene chloride and absolute methanol at -40~-50° followed by introduction of gaseous ammonia (6) gave the dihydrofuran **2** in 96% yield. The nmr spectrum (7) of **2** showed that it was an approximately equimolar mixture of *trans* and *cis* isomers, which could be separated by fractional recrystallization from ether-*n*-hexane. The physical, analytical and spectral data for each of the isomers are as follows: m.p. 119.5-120.5°. *Anal.* Calcd. for C<sub>16</sub>H<sub>17</sub>NO<sub>5</sub>: C, 63.36; H, 5.65; N, 4.62. Found: C, 63.63; H, 5.53; N, 4.83; nmr 1.51 (3H, s, 1-CH<sub>3</sub>), 3.08 (3H, s, OCH<sub>3</sub>), 3.19 (3H, s, OCH<sub>3</sub>),  $\nu_A$  4.01 and  $\nu_B$  3.96 (2H, AB system,  $J = 14.0$  Hz, CH<sub>2</sub>N), 5.86 (2H, s, CH=CH), 7.55~7.88 (4H, m, C<sub>6</sub>H<sub>4</sub>); m.p. 89.5-91.0°; nmr: 1.27 (3H, s, 1-CH<sub>3</sub>), 3.29 (3H, s, OCH<sub>3</sub>), 3.33 (3H, s, OCH<sub>3</sub>), 3.97 (2H, s, CH<sub>2</sub>N), 5.89 (2H, s, CH=CH), 7.59~7.93 (4H, m, C<sub>6</sub>H<sub>4</sub>).

Catalytic hydrogenation of **2** with the higher melting point using Raney nickel in ethanol afforded the tetrahydrofuran **3** in 96% yield (8) [m.p. 113.4-114.5° (recrystallized from ether-*n*-hexane)]. *Anal.* Calcd. for C<sub>16</sub>H<sub>19</sub>NO<sub>5</sub>: C, 62.94; H, 6.27; N, 4.59. Found: C, 62.88; H, 6.29; N, 4.74; nmr:  $\delta$  1.47 (3H, s, 1-CH<sub>3</sub>,

1.77~2.56 (4H, m, CH<sub>2</sub>CH<sub>2</sub>), 3.16 (3H, s, OCH<sub>3</sub>), 3.33 (3H, s, OCH<sub>3</sub>),  $\nu_A$  4.06 and  $\nu_B$  3.84 (2H, AB system,  $J = 14.0$  Hz, CH<sub>2</sub>N), 7.60~7.91 (4H, m, C<sub>6</sub>H<sub>4</sub>).

Condensation of 2-amino-5-chlorobenzophenone with **3** in benzene with *p*-toluenesulfonic acid as catalyst gave the pyrrolylbenzophenone **4** in 87% yield [m.p. 148.5-149.5° (recrystallized from ether-*n*-hexane)]. *Anal.* Calcd. for C<sub>27</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub>: C, 71.29; H, 4.21; N, 6.16. Found: C, 71.27; H, 3.97; N, 6.18; nmr:  $\delta$  1.89 (3H, s, CH<sub>3</sub>),  $\nu_A$  4.57 and  $\nu_B$  4.39 (2H, AB system,  $J = 15.0$  Hz, CH<sub>2</sub>N),  $\nu_A$  6.03 and  $\nu_B$  5.69 (2H, AB system,  $J =$



benzene rings)].

Removal of the phthaloyl group from **4** and ring closure to 8-chloro-1-methyl-6-phenyl-4*H*-pyrrolo[1,2-*a*]-[1,4]benzodiazepine (**5**) was effected by heating at reflux a solution of **4** in ethanol with hydrazine hydrate (in 67%). Most of the phthalazine generated in the reaction could be removed as solid by filtration from the cooled reaction mixture. Chromatographic isolation followed by recrystallization from ether-*n*-hexane gave **5** as slightly yellow prisms showing m.p. 142.5-143.5°. Infrared absorption was recorded at 1607, 1480, 1444, 1410 and 1299 cm<sup>-1</sup>. The nmr spectrum had  $\delta$  2.33 (3H, s, CH<sub>3</sub>),  $\nu_A$  4.97 and  $\nu_B$  3.95 (2H, AB system, J = 12.5 Hz, CH<sub>2</sub>N), 7.02 (2H, m, =CH-CH=), 7.18~7.60 (8H, m, protons on two benzene rings). *Anal.* Calcd. for C<sub>19</sub>H<sub>15</sub>ClN<sub>2</sub>: C, 74.39; H, 4.93; N, 9.13; Cl, 11.56. Found: C, 74.29; H, 4.76; N, 9.06; Cl, 11.55.

#### Acknowledgments.

The authors are indebted to Misses K. Tatebe and N. Igarashi for microanalyses. Particular appreciation is expressed to Dr. T. Noguchi, Dr. S. Tsunoda and Mr. S. Ishimoto for their advice and support during the course of this work.

#### REFERENCES AND NOTES

- (1) For Part I in this series see Takeshi Hara, Kazuhiko Itoh and Nobuhiro Itoh, *J. Heterocyclic Chem.*, **13**, 1233 (1976).
- (2) To whom correspondence should be addressed.
- (3a) J. B. Hester, Jr. and A. R. Hanze (to Upjohn), U. S. Patent 3,917,627 (1975); (b) J. P. Maffrand, G. Ferrand and F. Eloy, *Eur. J. Med. Chem.-Chim. Ther.*, **9**, 539 (1974); (c) Centre d'Etudes pour l'Industrie Pharmaceutique, German Patent 2,321,705 (1973); (d) J. P. Maffrand, G. Ferrand and F. Eloy, *Tetrahedron Letters*, 3449 (1973).
- (4a) J. B. Hester, Jr., A. D. Rudzik and B. V. Kamder, *J. Med. Chem.*, **14**, 1078 (1971); (b) K. Megro, H. Tawada and Y. Kuwada, *Chem. Pharm. Bull.*, **21**, 1619 (1973).
- (5) E. E. Garcia, J. G. Riley and R. I. Fryer, *J. Org. Chem.*, **33**, 1359 (1968).
- (6) J. Fakstorp, D. Raleigh and L. E. Schniepp, *J. Am. Chem. Soc.*, **72**, 869 (1950).
- (7) All the nmr spectra were recorded by a JOEL JNM-MH-100 nuclear magnetic resonance spectrometer in deuteriochloroform with tetramethylsilane as an internal standard.
- (8) As either *trans* or *cis* isomer of **3** can be equally employed for the present synthesis, the separation of the isomers of **2** is not necessary for the synthetic purpose. A mixture of *trans* and *cis* isomers of **2** was successfully transformed to a mixture of the stereoisomers of **3**, and then to compound **4**.